Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Chaperone directed heterobifunctional molecules circumvent KRASG12C inhibitor resistance.

Cancer letters - 10 Jul 2025

Pulido Ines, Luan Qiyue, Pastor-Puente Sara, Gunder Laura, Wang Yaya, Ying Chenghao, Li Jinhua, Sun Yuetong, Dai Yan, Ascoli Christian, Abdelhady Khaled, Massad Malek, Prince Thomas L, Wang Guoqiang, Foley Kevin P, Ying Weiwen, Papautsky Ian, Carretero Julian, Shimamura Takeshi

Abstract excerpt

While KRASG12C inhibitors have shown promising results in clinical activity, acquired resistance remains a significant barrier to durable responses. Combination therapies have been explored to improve the efficacy of KRASG12C inhibitors; however, their use is often restricted due to toxicity and limitations in clinically amenable dosing schedules. Transcriptomic profiling and functional assays on acquired...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HSP90 Heat-Shock Proteins

Share to Mice, Nude

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 40204148
DOI: 10.1016/j.canlet.2025.217691
PMCID: PMC13276862

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Chaperone directed heterobifunctional molecules circumvent KRASG12C inhibitor resistance.PMID 40204148Read ↗

Dual Inhibitors of KRASG12D and HSP90 Are Effective against KRASG12D Inhibitor Resistance.Semantic proximity Read ↗

The evolving landscape of KRAS-targeted therapy: mechanisms of resistance and emerging strategies.Semantic proximity Read ↗

Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies.Semantic proximity Read ↗

Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance.Semantic proximity Read ↗

Resistance looms for KRAS G12C inhibitors and rational tackling strategies.Semantic proximity Read ↗

Multiple initiatives to conquer KRAS G12C inhibitor resistance from the perspective of clinical therapy.Semantic proximity Read ↗

Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer.Semantic proximity Read ↗

Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors.Semantic proximity Read ↗

Acquired Resistance to KRASG12C Inhibition in Cancer.Semantic proximity Read ↗

KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone.Semantic proximity Read ↗

Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culpritSemantic proximity Read ↗

Combinatorial approaches for mitigating resistance to KRAS-targeted therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.